Urovant Sciences (NASDAQ:UROV) Issues Earnings Results
Urovant Sciences (NASDAQ:UROV) announced its earnings results on Thursday. The company reported ($0.96) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.96), Fidelity Earnings reports.
Shares of Urovant Sciences stock traded up $0.24 during trading hours on Friday, reaching $7.79. 12,452 shares of the company were exchanged, compared to its average volume of 60,245. Urovant Sciences has a 1 year low of $4.05 and a 1 year high of $14.49.
In related news, major shareholder Qvt Associates Gp Llc acquired 21,338 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were acquired at an average price of $8.31 per share, with a total value of $177,318.78. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Patrick Machado acquired 21,608 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were bought at an average cost of $7.54 per share, for a total transaction of $162,924.32. The disclosure for this purchase can be found here. Insiders have bought 127,737 shares of company stock worth $1,001,153 in the last ninety days.
ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/urovant-sciences-nasdaqurov-issues-earnings-results/3041484.html.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
See Also: Outstanding Shares
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.